LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

Search

AxoGen Inc

Suletud

SektorTervishoid

41.84 -3.15

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

41.63

Max

43.41

Põhinäitajad

By Trading Economics

Sissetulek

-6.4M

-20M

Müük

1.6M

61M

Aktsiakasum

0.07

Kasumimarginaal

-31.866

Töötajad

622

EBITDA

5.7M

-2.8M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+15.32% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

4. aug 2026

Turustatistika

By TradingEconomics

Turukapital

223M

2.3B

Eelmine avamishind

44.99

Eelmine sulgemishind

41.84

Uudiste sentiment

By Acuity

12%

88%

20 / 347 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

AxoGen Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

25. aug 2025, 11:48 UTC

Suurimad hinnamuutused turgudel

Axogen Shares Fall Premarket as FDA Extends Avance Review

Võrdlus sarnastega

Hinnamuutus

AxoGen Inc Prognoos

Hinnasiht

By TipRanks

15.32% tõus

12 kuu keskmine prognoos

Keskmine 50.14 USD  15.32%

Kõrge 55 USD

Madal 48 USD

Põhineb 7 Wall Streeti analüütiku instrumendi AxoGen Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

7 ratings

7

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

N/A / 14.4Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Neutral Evidence

Sentiment

By Acuity

20 / 347 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest AxoGen Inc

Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. Axogen, Inc. is headquartered in Alachua, Florida.
help-icon Live chat